Researchers enrolled 602 patients at elevated risk for post-ERCP pancreatitis in the study. They received either a single dose of the nonsteroidal antiinflammatory drug or placebo immediately after ERCP.
Post-ERCP pancreatitis developed in 27 of 295 patients (9.2 percent) in the indomethacin group and in 52 of 307 patients (16.9 percent) in the placebo group. Moderate-to-severe pancreatitis developed in 13 patients (4.4 percent) in the indomethacin group and in 27 patients (8.8 percent) in the placebo group.
Related Articles on New Research:
Study: Colorectal Cancer Screenings Increase When Patients Given Options
Study: Patients With GI Disorders May Receive Significant Doses of Diagnostic Radiation
Study: Adult Irritable Bowel Syndrome Linked to Childhood Trauma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
